iLRRK2 Wild-Type and Mutant (G2019S) Transgenic Mice

Reference #:

2007-330

Inventors/Contributors

Jada M. Lewis, Ph.D., Charles A. Wuertzer, Ph.D., Matthew J. Farrer, Ph.D., Sarah J. Lincoln

Description

We created mice that contain human LRRK2 cDNA encoding either the wild-type or G2019S mutant form of the gene (hereafter termed "responder line(s)." The cDNA in these animals has been placed behind a minimal CMV promoter containing TetO and will only produce human LRRK2 protein when combined (in bigenic mice) with tTA. We have demonstrated in COS7 cells that the human LRRK2 expression from these constructs occurs in presence of tTA and is supressed by the administration of doxycycline in media. Founders have been created and have been screened for the presence of either wild-type or G2019S mutant LRRK2. Founders have been bred to FVB/N to maintain the original background of the "responder" lines. Additionally, the LRRK2 wild-type and mutant responder lines have been bred with the CamKlla-tTA mice to generate inducible LRRK2 lines (iLRRK2 and iLRRK2G2019S).

Patent Status

None